Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Coherus Bio (CHRS)

Coherus Bio (CHRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Coherus Bio 333 TWIN DOLPHIN DRIVE SUITE 600 REDWOOD CITY CA 94065 USA

www.coherus.com P: 650-649-3530

Description:

Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.

Key Statistics

Overview:

Market Capitalization, $K 247,426
Enterprise Value, $K 391,016
Shares Outstanding, K 113,498
Annual Sales, $ 257,240 K
Annual Net Income, $ -237,890 K
Last Quarter Sales, $ 91,520 K
Last Quarter Net Income, $ -79,650 K
EBIT, $ -203,210 K
EBITDA, $ -199,420 K
60-Month Beta 0.54
% of Insider Shareholders 10.99%
% of Institutional Shareholders 72.82%
Float, K 101,025
% Float 89.01%
Short Volume Ratio 0.55

Growth:

1-Year Return -73.73%
3-Year Return -85.27%
5-Year Return -86.69%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 24.53%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.62 on 03/13/24
Latest Earnings Date 05/13/24
Earnings Per Share ttm -2.48
EPS Growth vs. Prev Qtr -89.47%
EPS Growth vs. Prev Year 5.26%
Annual Dividend Yield 0.00%
Dividend Payable Date 01/16/95
Dividend Payout Ratio 0.00%

CHRS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -44.16%
Profit Margin % -92.48%
Debt/Equity -1.27
Price/Sales 0.96
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -1.74
Interest Coverage -4.88
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar